| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Catheterization | 15 | 2019 | 291 | 4.700 |
Why?
|
| Heart-Assist Devices | 11 | 2018 | 731 | 3.030 |
Why?
|
| Heart Arrest | 13 | 2018 | 265 | 2.250 |
Why?
|
| Aortic Valve Insufficiency | 5 | 2017 | 130 | 2.190 |
Why?
|
| Septal Occluder Device | 11 | 2020 | 42 | 2.160 |
Why?
|
| Ventricular Fibrillation | 10 | 2016 | 65 | 2.000 |
Why?
|
| Myocardial Infarction | 9 | 2024 | 376 | 1.970 |
Why?
|
| Shock, Cardiogenic | 5 | 2016 | 95 | 1.920 |
Why?
|
| Cardiopulmonary Resuscitation | 9 | 2019 | 191 | 1.920 |
Why?
|
| Myocardial Ischemia | 7 | 2024 | 162 | 1.900 |
Why?
|
| Heart Valve Prosthesis Implantation | 6 | 2023 | 166 | 1.700 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2019 | 140 | 1.670 |
Why?
|
| Coronary Vessels | 8 | 2024 | 177 | 1.630 |
Why?
|
| Echocardiography, Transesophageal | 11 | 2020 | 344 | 1.590 |
Why?
|
| Heart Septal Defects, Ventricular | 3 | 2019 | 67 | 1.560 |
Why?
|
| Ventricular Function, Left | 7 | 2021 | 592 | 1.520 |
Why?
|
| Coronary Angiography | 15 | 2024 | 232 | 1.520 |
Why?
|
| Popliteal Artery | 2 | 2020 | 27 | 1.470 |
Why?
|
| Absorbable Implants | 2 | 2020 | 34 | 1.450 |
Why?
|
| Heart Failure | 9 | 2021 | 1204 | 1.440 |
Why?
|
| Angioplasty, Balloon | 2 | 2020 | 95 | 1.410 |
Why?
|
| Peripheral Arterial Disease | 2 | 2020 | 88 | 1.350 |
Why?
|
| Ischemia | 2 | 2020 | 243 | 1.270 |
Why?
|
| Treatment Outcome | 34 | 2024 | 7998 | 1.220 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2019 | 462 | 1.120 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2020 | 58 | 1.080 |
Why?
|
| Aortic Valve | 4 | 2023 | 222 | 1.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 8 | 2012 | 66 | 1.060 |
Why?
|
| Endothelin-1 | 3 | 2011 | 41 | 1.060 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 4 | 2020 | 67 | 1.040 |
Why?
|
| Aortic Valve Stenosis | 5 | 2023 | 131 | 1.020 |
Why?
|
| Coronary Artery Disease | 6 | 2024 | 350 | 1.000 |
Why?
|
| Ultrasonography, Interventional | 3 | 2023 | 121 | 1.000 |
Why?
|
| Prosthesis Design | 7 | 2019 | 278 | 0.870 |
Why?
|
| Male | 53 | 2022 | 40988 | 0.860 |
Why?
|
| Endovascular Procedures | 2 | 2017 | 218 | 0.850 |
Why?
|
| Pulmonary Embolism | 6 | 2021 | 222 | 0.840 |
Why?
|
| Echocardiography, Three-Dimensional | 6 | 2020 | 516 | 0.830 |
Why?
|
| Thrombolytic Therapy | 5 | 2021 | 220 | 0.810 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 187 | 0.800 |
Why?
|
| Stents | 4 | 2012 | 377 | 0.780 |
Why?
|
| Catheterization | 4 | 2017 | 232 | 0.770 |
Why?
|
| Humans | 68 | 2024 | 86678 | 0.770 |
Why?
|
| Middle Aged | 28 | 2020 | 25040 | 0.720 |
Why?
|
| Hemodynamics | 5 | 2013 | 711 | 0.710 |
Why?
|
| Registries | 5 | 2020 | 703 | 0.700 |
Why?
|
| Aged | 27 | 2020 | 18423 | 0.670 |
Why?
|
| Retrospective Studies | 21 | 2023 | 8496 | 0.660 |
Why?
|
| Hospital Costs | 1 | 2019 | 107 | 0.640 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 59 | 0.620 |
Why?
|
| Coronary Artery Bypass | 3 | 2023 | 228 | 0.620 |
Why?
|
| Balloon Occlusion | 3 | 2012 | 27 | 0.620 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 45 | 0.620 |
Why?
|
| Clinical Protocols | 1 | 2018 | 156 | 0.610 |
Why?
|
| Computed Tomography Angiography | 2 | 2020 | 131 | 0.610 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2018 | 41 | 0.610 |
Why?
|
| Heart Ventricles | 2 | 2020 | 760 | 0.610 |
Why?
|
| Arteriovenous Fistula | 1 | 2018 | 52 | 0.610 |
Why?
|
| Blood Circulation | 1 | 2017 | 29 | 0.600 |
Why?
|
| Heart Massage | 1 | 2017 | 12 | 0.600 |
Why?
|
| Swine | 13 | 2016 | 555 | 0.600 |
Why?
|
| Venae Cavae | 1 | 2017 | 14 | 0.600 |
Why?
|
| Transposition of Great Vessels | 1 | 2017 | 23 | 0.600 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 125 | 0.590 |
Why?
|
| Aminophylline | 1 | 2016 | 14 | 0.590 |
Why?
|
| Device Removal | 1 | 2018 | 161 | 0.590 |
Why?
|
| Bradycardia | 1 | 2016 | 39 | 0.580 |
Why?
|
| Female | 37 | 2022 | 44550 | 0.580 |
Why?
|
| Heart Septal Defects | 1 | 2016 | 31 | 0.580 |
Why?
|
| Fibrinolytic Agents | 3 | 2021 | 202 | 0.570 |
Why?
|
| Cardiomyopathies | 2 | 2018 | 240 | 0.570 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 111 | 0.560 |
Why?
|
| Dyspnea | 1 | 2016 | 73 | 0.560 |
Why?
|
| Constriction, Pathologic | 1 | 2017 | 213 | 0.560 |
Why?
|
| Postoperative Complications | 3 | 2017 | 2207 | 0.550 |
Why?
|
| Balloon Valvuloplasty | 1 | 2015 | 8 | 0.550 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 27 | 0.550 |
Why?
|
| Disease Management | 1 | 2018 | 327 | 0.540 |
Why?
|
| Vascular Fistula | 1 | 2015 | 12 | 0.540 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 99 | 0.530 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 129 | 0.520 |
Why?
|
| Fontan Procedure | 1 | 2015 | 53 | 0.520 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2020 | 134 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 1037 | 0.510 |
Why?
|
| Ventricular Septum | 1 | 2014 | 11 | 0.510 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 72 | 0.500 |
Why?
|
| Heart Injuries | 1 | 2014 | 16 | 0.500 |
Why?
|
| Electrocardiography | 4 | 2012 | 478 | 0.500 |
Why?
|
| Epinephrine | 2 | 2011 | 84 | 0.490 |
Why?
|
| Iatrogenic Disease | 1 | 2014 | 69 | 0.490 |
Why?
|
| Adenosine | 1 | 2016 | 225 | 0.480 |
Why?
|
| Time Factors | 10 | 2021 | 5214 | 0.470 |
Why?
|
| Aneurysm, False | 1 | 2014 | 54 | 0.470 |
Why?
|
| Echocardiography, Doppler, Color | 4 | 2015 | 103 | 0.460 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2014 | 87 | 0.440 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 238 | 0.430 |
Why?
|
| Risk Assessment | 8 | 2020 | 2264 | 0.430 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 351 | 0.430 |
Why?
|
| Foramen Ovale, Patent | 1 | 2012 | 18 | 0.430 |
Why?
|
| Biomarkers | 3 | 2019 | 1718 | 0.410 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2013 | 162 | 0.400 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 6513 | 0.400 |
Why?
|
| Thymosin | 1 | 2011 | 6 | 0.400 |
Why?
|
| Coronary Aneurysm | 1 | 2011 | 16 | 0.390 |
Why?
|
| Polytetrafluoroethylene | 1 | 2011 | 74 | 0.390 |
Why?
|
| Electric Countershock | 2 | 2011 | 47 | 0.380 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 45 | 0.380 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 150 | 0.370 |
Why?
|
| Coronary Disease | 2 | 2012 | 261 | 0.370 |
Why?
|
| Vascular Patency | 2 | 2020 | 126 | 0.360 |
Why?
|
| Disease Models, Animal | 10 | 2016 | 2231 | 0.360 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 183 | 0.350 |
Why?
|
| Mitral Valve | 3 | 2020 | 248 | 0.350 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 225 | 0.350 |
Why?
|
| After-Hours Care | 1 | 2008 | 8 | 0.340 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 407 | 0.340 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 1802 | 0.330 |
Why?
|
| Coronary Thrombosis | 1 | 2008 | 14 | 0.320 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2020 | 187 | 0.310 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2007 | 11 | 0.310 |
Why?
|
| Medical Errors | 1 | 2008 | 115 | 0.310 |
Why?
|
| Coronary Circulation | 3 | 2024 | 130 | 0.300 |
Why?
|
| United States | 7 | 2020 | 6681 | 0.300 |
Why?
|
| Hypoxia | 1 | 2012 | 641 | 0.290 |
Why?
|
| Risk Factors | 8 | 2021 | 5420 | 0.290 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3642 | 0.280 |
Why?
|
| Thrombectomy | 1 | 2008 | 158 | 0.280 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 1673 | 0.280 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 303 | 0.270 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 220 | 0.270 |
Why?
|
| Adult | 11 | 2024 | 25659 | 0.270 |
Why?
|
| Artifacts | 1 | 2007 | 244 | 0.260 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 394 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2008 | 378 | 0.250 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2015 | 78 | 0.250 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 455 | 0.250 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2004 | 62 | 0.250 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 332 | 0.240 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 95 | 0.240 |
Why?
|
| Heart Transplantation | 2 | 2023 | 705 | 0.230 |
Why?
|
| Cysteine | 1 | 2024 | 135 | 0.230 |
Why?
|
| Heart Diseases | 2 | 2016 | 290 | 0.230 |
Why?
|
| Clinical Competence | 1 | 2008 | 756 | 0.220 |
Why?
|
| Microcirculation | 2 | 2024 | 106 | 0.210 |
Why?
|
| Ulnar Artery | 1 | 2022 | 5 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 1376 | 0.210 |
Why?
|
| Survival Rate | 5 | 2019 | 1864 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2013 | 683 | 0.210 |
Why?
|
| Radial Artery | 1 | 2022 | 33 | 0.210 |
Why?
|
| Aorta | 2 | 2020 | 281 | 0.200 |
Why?
|
| Stroke Volume | 3 | 2021 | 456 | 0.200 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 827 | 0.200 |
Why?
|
| Acute Disease | 3 | 2021 | 826 | 0.190 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 1921 | 0.190 |
Why?
|
| Transillumination | 1 | 2020 | 9 | 0.190 |
Why?
|
| Limb Salvage | 1 | 2020 | 33 | 0.190 |
Why?
|
| Ultrasonography | 3 | 2015 | 695 | 0.190 |
Why?
|
| Reoperation | 2 | 2013 | 597 | 0.190 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 11 | 0.180 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2011 | 78 | 0.180 |
Why?
|
| Resuscitation | 2 | 2011 | 100 | 0.180 |
Why?
|
| Recovery of Function | 2 | 2018 | 272 | 0.180 |
Why?
|
| Animals | 14 | 2016 | 26590 | 0.180 |
Why?
|
| Coronary Restenosis | 3 | 2010 | 11 | 0.170 |
Why?
|
| Fluoroscopy | 1 | 2019 | 119 | 0.170 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 243 | 0.170 |
Why?
|
| Saphenous Vein | 2 | 2010 | 61 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 138 | 0.160 |
Why?
|
| Monocytes | 1 | 2019 | 216 | 0.160 |
Why?
|
| Echocardiography | 4 | 2020 | 911 | 0.160 |
Why?
|
| Microvessels | 1 | 2018 | 70 | 0.150 |
Why?
|
| Recurrence | 2 | 2012 | 1139 | 0.150 |
Why?
|
| Arterial Switch Operation | 1 | 2017 | 5 | 0.150 |
Why?
|
| Triage | 1 | 2018 | 108 | 0.150 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2016 | 6 | 0.150 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2016 | 5 | 0.150 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 237 | 0.150 |
Why?
|
| Renal Veins | 1 | 2017 | 28 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 385 | 0.150 |
Why?
|
| Emergency Service, Hospital | 3 | 2016 | 484 | 0.150 |
Why?
|
| Tumor Necrosis Factors | 1 | 2016 | 14 | 0.150 |
Why?
|
| Heart Atria | 2 | 2016 | 250 | 0.150 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 148 | 0.140 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 35 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 160 | 0.140 |
Why?
|
| Bioprosthesis | 1 | 2016 | 36 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 47 | 0.140 |
Why?
|
| Macrophages | 1 | 2019 | 557 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2019 | 973 | 0.140 |
Why?
|
| Cannula | 1 | 2016 | 47 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2019 | 816 | 0.140 |
Why?
|
| Equipment Failure | 1 | 2016 | 119 | 0.140 |
Why?
|
| Length of Stay | 1 | 2019 | 704 | 0.130 |
Why?
|
| Subclavian Artery | 1 | 2015 | 44 | 0.130 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 96 | 0.130 |
Why?
|
| Atrial Appendage | 1 | 2015 | 26 | 0.130 |
Why?
|
| Prognosis | 3 | 2020 | 3680 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 296 | 0.120 |
Why?
|
| Random Allocation | 4 | 2020 | 332 | 0.120 |
Why?
|
| Comorbidity | 2 | 2015 | 944 | 0.120 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 73 | 0.120 |
Why?
|
| Aortography | 1 | 2014 | 63 | 0.120 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2013 | 16 | 0.120 |
Why?
|
| Infusions, Parenteral | 1 | 2013 | 50 | 0.120 |
Why?
|
| Amiodarone | 1 | 2013 | 12 | 0.120 |
Why?
|
| Contrast Media | 1 | 2018 | 1078 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 3362 | 0.120 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2013 | 68 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 2601 | 0.110 |
Why?
|
| International Normalized Ratio | 1 | 2013 | 38 | 0.110 |
Why?
|
| Dobutamine | 1 | 2013 | 61 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 2706 | 0.110 |
Why?
|
| Thrombosis | 1 | 2016 | 296 | 0.110 |
Why?
|
| Heart | 2 | 2020 | 539 | 0.110 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 49 | 0.110 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2013 | 58 | 0.110 |
Why?
|
| Software | 1 | 2017 | 654 | 0.110 |
Why?
|
| Catheter Ablation | 1 | 2015 | 233 | 0.110 |
Why?
|
| Kidney | 1 | 2018 | 1242 | 0.110 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 108 | 0.110 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2012 | 6 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2014 | 280 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 663 | 0.110 |
Why?
|
| Exercise Test | 1 | 2013 | 164 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2016 | 1538 | 0.110 |
Why?
|
| Mitral Valve Stenosis | 1 | 2012 | 37 | 0.100 |
Why?
|
| Labetalol | 1 | 2011 | 6 | 0.100 |
Why?
|
| Metoprolol | 1 | 2011 | 30 | 0.100 |
Why?
|
| Vascular Resistance | 2 | 2024 | 102 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 288 | 0.100 |
Why?
|
| Radiography, Interventional | 1 | 2012 | 150 | 0.100 |
Why?
|
| Catheters | 2 | 2021 | 74 | 0.100 |
Why?
|
| California | 2 | 2010 | 138 | 0.100 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 141 | 0.100 |
Why?
|
| Regenerative Medicine | 1 | 2011 | 23 | 0.100 |
Why?
|
| Infliximab | 4 | 2013 | 151 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 865 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 456 | 0.100 |
Why?
|
| Vasopressins | 1 | 2010 | 49 | 0.100 |
Why?
|
| Drug-Eluting Stents | 1 | 2010 | 16 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 243 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 152 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 268 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 96 | 0.090 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2010 | 99 | 0.090 |
Why?
|
| Critical Illness | 1 | 2012 | 294 | 0.090 |
Why?
|
| Sirolimus | 1 | 2010 | 170 | 0.090 |
Why?
|
| Endothelin-2 | 1 | 2008 | 1 | 0.090 |
Why?
|
| Endothelin-3 | 1 | 2008 | 2 | 0.090 |
Why?
|
| Ventricular Premature Complexes | 1 | 2008 | 7 | 0.080 |
Why?
|
| Electric Stimulation | 1 | 2010 | 347 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2013 | 1144 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2010 | 460 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 2009 | 131 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1992 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 346 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 715 | 0.080 |
Why?
|
| Chicago | 1 | 2013 | 1380 | 0.080 |
Why?
|
| Heart Rate | 1 | 2010 | 492 | 0.080 |
Why?
|
| Fatigue | 1 | 2008 | 174 | 0.080 |
Why?
|
| Workload | 1 | 2008 | 128 | 0.080 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 93 | 0.080 |
Why?
|
| Selection Bias | 1 | 2007 | 37 | 0.080 |
Why?
|
| Cell Movement | 1 | 2011 | 758 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2008 | 137 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2008 | 224 | 0.070 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2005 | 30 | 0.070 |
Why?
|
| Cytokines | 1 | 2009 | 778 | 0.070 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 39 | 0.070 |
Why?
|
| Observer Variation | 1 | 2007 | 603 | 0.070 |
Why?
|
| Metals | 1 | 2005 | 90 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 977 | 0.060 |
Why?
|
| Action Potentials | 1 | 2008 | 573 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1458 | 0.060 |
Why?
|
| Patient Selection | 2 | 2020 | 686 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 508 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 636 | 0.060 |
Why?
|
| Caspases | 1 | 2003 | 155 | 0.060 |
Why?
|
| Young Adult | 1 | 2015 | 5980 | 0.060 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 208 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 234 | 0.050 |
Why?
|
| Spasm | 1 | 2022 | 16 | 0.050 |
Why?
|
| Preoperative Care | 2 | 2015 | 397 | 0.050 |
Why?
|
| Ventricular Pressure | 1 | 2021 | 34 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2021 | 84 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1807 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2023 | 464 | 0.050 |
Why?
|
| Pulmonary Valve | 1 | 2020 | 32 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2020 | 156 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2018 | 4214 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 364 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1239 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 268 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 22 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 350 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 294 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 680 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2021 | 408 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2019 | 458 | 0.040 |
Why?
|
| Equipment Design | 1 | 2018 | 407 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 16 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 339 | 0.040 |
Why?
|
| Apoptosis | 1 | 2003 | 1683 | 0.040 |
Why?
|
| Phlebography | 1 | 2017 | 66 | 0.040 |
Why?
|
| Quality of Life | 1 | 2004 | 1585 | 0.040 |
Why?
|
| Illinois | 1 | 2018 | 462 | 0.040 |
Why?
|
| Oxygen | 1 | 2021 | 726 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 360 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 295 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 278 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 297 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 2013 | 13 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 351 | 0.030 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2013 | 6 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2013 | 18 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 563 | 0.030 |
Why?
|
| Etanercept | 1 | 2013 | 32 | 0.030 |
Why?
|
| Lidocaine | 1 | 2013 | 63 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2013 | 179 | 0.030 |
Why?
|
| Heart Arrest, Induced | 1 | 2013 | 31 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 88 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2013 | 148 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 93 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 152 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 674 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2011 | 45 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2011 | 229 | 0.020 |
Why?
|
| Adrenergic Antagonists | 1 | 2010 | 2 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 308 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 584 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 78 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 364 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 155 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1830 | 0.020 |
Why?
|
| Cardiology Service, Hospital | 1 | 2008 | 4 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 263 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1852 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 216 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 860 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 923 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1055 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2006 | 54 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2008 | 209 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2003 | 25 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2003 | 33 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 912 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2003 | 59 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 148 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 636 | 0.010 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 467 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 1578 | 0.010 |
Why?
|